03:43 AM EDT, 05/14/2026 (MT Newswires) -- AstraZeneca (AZN) said Thursday that a combination of its Imfinzi drug and enfortumab vedotin showed significant improvements in event-free and overall survival rates in a phase 3 muscle-invasive bladder cancer trial.

The mid-term analysis of the study focused on patients who were unable to receive or declined standard cisplatin chemotherapy by itself, the company said.

Another trial arm that added Imjudo to the combination demonstrated improved event-free survival, although overall survival data have not yet reached statistical significance, AstraZeneca said.

The safety profile for the treatments remained consistent with previously known data, and no new safety concerns were identified, the drugmaker said.